Aspirin Per Se (i.e., 2-(acetyloxy)benozic Acid) Patents (Class 514/165)
  • Publication number: 20040171585
    Abstract: In accordance with the present invention, there are provided therapeutically effective compounds comprising an amphipathic carboxylate of the formula R—COOH, or a salt or an ester or amide of such compound, where R designates a saturated or unsaturated alkyl chain of 10-24 carbon atoms, one or more of which may be replaced by heteroatoms, where one or more of said carbon or heteroatom chain members optionally forms part of a ring, and where said chain is optionally substituted by a hydrocarbyl radical, heterocyclyl radical, lower alkoxy, hydroxyl-substituted lower alkyl, hydroxyl, carboxyl, halogen, phenyl or (hydroxy-, lower alkyl-, lower alkoxy-, lower alkenyl- or lower alkinyl)-substituted phenyl, C3-C7 cycloalkyl or (hydroxy-, lower alkyl-, lower alkoxy-, lower alkenyl- or lower alkinyl)-substituted C3-C7 cycloalkyl wherein said amphipathic carboxylate is capable of being endogenously converted to its respective coenzyme A thioester.
    Type: Application
    Filed: December 11, 2003
    Publication date: September 2, 2004
    Inventor: Jacob Bar-Tana
  • Publication number: 20040171682
    Abstract: Nitro-oxyderivative compounds or salts thereof having the following general formula (I): A-(B)b0-(C)c0-NO2 wherein: c0 is an integer and is 0 or 1, b0 is an integer and is 0 or 1, A=R-T1-, wherein R is the radical of an analgesic drug for the chronic pain, in particular for the neuropathic pain; B is such that its precursor is selected from anminoacids, hydroxyacids, polyalcohols, compounds containing at least one acid function; C is a bivalent radical containing an aliphatic, heterocyclic or aromatic radical.
    Type: Application
    Filed: December 19, 2003
    Publication date: September 2, 2004
    Inventors: Piero Del Soldato, Ennio Ongini
  • Publication number: 20040170676
    Abstract: The present invention relates to the discovery of a transdermal delivery system that can deliver high molecular weight pharmaceuticals and cosmetic agents to skin cells. A novel transdermal delivery system with therapeutic and cosmetic application and methods of use of the foregoing is disclosed.
    Type: Application
    Filed: February 27, 2004
    Publication date: September 2, 2004
    Inventor: Frederick L. Jordan
  • Patent number: 6780508
    Abstract: Carriers for use in the preparation of mixtures for inhalation powders intended for pulmonary administration of micronized drugs by means of a dry powder inhaler and the method for their preparation are described.
    Type: Grant
    Filed: April 16, 2002
    Date of Patent: August 24, 2004
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventors: Giovanni Caponetti, Pier Luigi Catellani, Ruggero Bettini, Paolo Colombo, Paolo Ventura
  • Publication number: 20040162273
    Abstract: The present invention is directed to powder pharmaceutical compositions which are dissolvable in a liquid such as hot water, wherein the compositions provide for a therapeutic effect in the treatment of symptoms associated with the common cold and/or flu. These powder pharmaceutical compositions comprise a select pharmaceutical active that is especially effective in alleviating cold and/or flu symptoms.
    Type: Application
    Filed: January 23, 2003
    Publication date: August 19, 2004
    Applicant: The Procter & Gamble Company
    Inventors: Liza Elaine Achong, Oswaldo David Romero
  • Publication number: 20040157784
    Abstract: A composition comprising the tannate of an opioid. Suitable opioids include alfentanil, buprenorphine, butorphanol, carfentanil, cocaine, codeine, dezocine, diacetylmorphine, dihydrocodeine, dihydromorphine, diphenoxylate, diprenorphine, etorphine, fentanyl, heroin, hydrocodone, hydromorphone, &bgr;-hydroxy-3-methylfentanyl, levo-&agr;-acetylmethadol, levorphanol, lofentanil, meperidine, methadone, morphine, nalbuphine, nalmefene, o-methylnaltrexone, naloxone, naltrexone, oxycodone, oxymorphone, pentazocine, pethidine, propoxyphene, remifentanil, sufentanil, tilidine and tramadol. The opioid tannate may be readily prepared by reacting an opioid free base with tannic acid, either neat or in the presence of up to about 30 wt. % water, at a temperature of about 60 to about 150° C. and thereafter recovering the resultant opioid tannate. The opioid tannate may also be prepared by an alternative process that involves reacting the opioid free base with water at a temperature such that not more than about 10 wt.
    Type: Application
    Filed: December 12, 2003
    Publication date: August 12, 2004
    Applicant: Jame Fine Chemicals, Inc.
    Inventors: Vilas M. Chopdekar, Sham N. Redkar, James R. Schlek
  • Publication number: 20040156908
    Abstract: Catheters used for medical treatment, e.g., hemodialysis are filled with a locking solution, usually heparin between treatments. To prevent infections, antimicrobial or antibiotic substances have been used as locking solution alone or in combination with antithrombotic substances. It has been found that these locking solutions are rapidly washed out from the catheter tip. The invention describes a thixotropic gel that can be used as locking solution. Beneficial substances, e.g., antimicrobial or antibiotic substances can be added to the gel. A preferred antimicrobial substance is taurolidin alone or in combination with salicylic acid or one of its salts.
    Type: Application
    Filed: February 2, 2004
    Publication date: August 12, 2004
    Inventor: Hans-Dietrich Polaschegg
  • Publication number: 20040147581
    Abstract: Compositions and methods to treat or prevent pain, inflammation, or inflammation-related disorder, as well as a neurologic disorder involving neurodegrneration in a subject that is in need of such prevention or treatment involve a combination of a Cox-2 inhibitor and a 5-HT1A receptor modulator.
    Type: Application
    Filed: November 5, 2003
    Publication date: July 29, 2004
    Applicant: Pharmacia Corporation
    Inventors: Duncan P. Taylor, Diane T. Stephenson
  • Publication number: 20040147493
    Abstract: According to the invention, compositions are made available which have a strong cytotoxic effect which is largely selective on tumor tissue. The invention is based on the fact that certain benzoic acid derivatives have a strong synergistic effect as a mixture and destroy cancer cells selectively in a pH range of 7 or below, such as from 6.5 to 7.
    Type: Application
    Filed: November 17, 2003
    Publication date: July 29, 2004
    Inventor: Werner Kreutz
  • Publication number: 20040146498
    Abstract: The present invention provides novel pharmaceutical combinations and their use in anti-thrombotic therapy. The combinations comprise a compound of formula (I) or a pharmaceutically acceptable derivative thereof; formula (I), and another anti-thrombotic agent or a pharmaceutically acceptable derivative thereof.
    Type: Application
    Filed: November 25, 2003
    Publication date: July 29, 2004
    Inventors: John Dixon, Robert Humphries, Alexander Nicol
  • Publication number: 20040147606
    Abstract: Medicinal compositions characterized by containing fudosteine and an antipyretic/analgesic. These medicinal compositions are medicinal compositions to be used for common cold, etc. which have improved sputum-removal and antiinflammatory effects.
    Type: Application
    Filed: November 25, 2003
    Publication date: July 29, 2004
    Inventors: Yoichi Onuki, Minoru Okada, Hirokata Sakai, Hideyoshi Kanbe, Hiroyuki Mizuno, Katsumi Imamori
  • Publication number: 20040147498
    Abstract: Combinations of synthetic low molecular weight catalysts for the dismutation of superoxide and Nonsteroidal Analgesic/Anti-Inflammatory Drugs (NSAIDs) are potent analgesics that are effective in elevating the pain threshold in hyperalgesic conditions.
    Type: Application
    Filed: December 16, 2003
    Publication date: July 29, 2004
    Applicants: MetaPhore Pharmaceuticals, Inc., Pharmacia Corporation
    Inventor: Daniela Salvemini
  • Publication number: 20040147445
    Abstract: Compositions useful for treating inflammatory diseases including arthritis are disclosed which comprise cetyl myristoleate compounds or related compounds and at least one compound useful for treatment of inflammatory disease, such as tetracycline compounds, Cox-2 inhibitors, non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, local anaesthetics, chelating agents, matrix metalloprotease inhibitors, inhibitors of inflammatory cytokines, glucosamine, chondroitin sulfate and collagen hydrolysate. Also disclosed are pharmaceutical compositions and methods of treatment for inflammatory disease and local inflammation and dermal irritation. Also disclosed are compositions including tetracycline and at least one compound useful for treatment of inflammatory disease.
    Type: Application
    Filed: January 12, 2004
    Publication date: July 29, 2004
    Inventor: Bruce Levin
  • Patent number: 6761913
    Abstract: Biologically active extracts of celery seed are produced by controlled ethanolic extraction, distillation and drying, and further processing by supercritical fluid extractions (SFE), and may be further fractionated by column fractionation, distillation, LiAlH reduction and the like. These extracts possess activity for the treatment and prevention of acute and chronic pain, inflammation and gastrointestinal irritation.
    Type: Grant
    Filed: April 22, 2003
    Date of Patent: July 13, 2004
    Assignee: International Celery Development Alliance PTY. Ltd.
    Inventors: Desley Ethel Butters, Craig Kendall Charles Davis, Ross Peter McGeary, Michael Christopher Powanda, Kim Drummond Rainsford, Michael Wellesley Whitehouse
  • Publication number: 20040131676
    Abstract: Provided herein, are dosage forms comprising an NSAID, a buffer and a PPI, as well as methods of treating various maladies using the above dosage form.
    Type: Application
    Filed: December 19, 2003
    Publication date: July 8, 2004
    Inventor: Rajneesh Taneja
  • Publication number: 20040132795
    Abstract: The present invention involves methods and reagents for diagnosing and treating glaucoma and related disorders. Specifically, the invention relates to a method of identifying mutations in the TIGR gene of a glaucomatous patient and treating them with an effective amount of a non-steroidal anti-inflammatory drug. Additionally the invention allows the identification of individuals at risk for progressive increases in intraocular pressure, which is a risk factor for glaucoma; the invention thus also allows the identification of individuals among ocular hypertensive/glaucoma suspect groups at increased risk of visual field loss.
    Type: Application
    Filed: December 22, 2003
    Publication date: July 8, 2004
    Inventor: Jon Polansky
  • Publication number: 20040127471
    Abstract: Therapeutic methods for treatment of age associated memory impairment (AAMI), mild cognitive impairment (MCI), Alzheimer's disease (AD), cerebrovascular dementia (CVD), and related neurodegenerative conditions by administering an agent capable of inhibiting cell cycle progression, comprising administering one or more agents that are capable of inhibiting neuronal cell cycle progression at either an early cell cycle phase or generally, either alone or in combination with one or more agents capable of reducing mitogenic stimulation.
    Type: Application
    Filed: September 17, 2003
    Publication date: July 1, 2004
    Inventor: Barry Reisberg
  • Publication number: 20040127470
    Abstract: The present invention relates to a novel method of preventing and/or treating neoplasia disorders in a subject that is in need of such prevention or treatment by administering to the subject at least one Cox-2 inhibitor in combination with an EGF receptor antagonist. Compositions, pharmaceutical compositions and kits are also described.
    Type: Application
    Filed: August 29, 2003
    Publication date: July 1, 2004
    Applicant: Pharmacia Corporation
    Inventor: Jaime Masferrer
  • Publication number: 20040121004
    Abstract: Provided herein, are dosage forms comprising an NSAID, a buffer and a PPI, as well as methods of treating various maladies using the above dosage form.
    Type: Application
    Filed: December 20, 2002
    Publication date: June 24, 2004
    Inventor: Rajneesh Taneja
  • Publication number: 20040115265
    Abstract: A multilayered tablet having three or more layers is provided which is useful for cholesterol lowering and reducing the risk of a myocardial infarction, which includes a first layer containing aspirin, another layer containing pravastatin, and a middle barrier layer, which preferably contains a buffering agent, which separates the first layer containing aspirin from the other layer containing pravastatin, and prevents or minimizes interaction of aspirin with pravastatin. A method for lowering cholesterol and reducing risk of a myocardial infarction employing such composition is also provided.
    Type: Application
    Filed: December 11, 2002
    Publication date: June 17, 2004
    Inventors: Loutfy Benkerrour, Olivier Galley, Francoise Quinet, Admassu Abebe, Peter Timmins
  • Publication number: 20040116356
    Abstract: The invention provides compositions and methods that employ compounds that can stimulate proliferation of fibroblasts or keratinocytes and/or stimulate production of collagen by fibroblasts. These compositions and methods are useful for treating gum- and skin-related conditions.
    Type: Application
    Filed: December 16, 2002
    Publication date: June 17, 2004
    Inventor: Sohail Malik
  • Publication number: 20040116393
    Abstract: The present invention relates to a method for prevention of epithelial cancer such as lung, bladder, prostate or gynaecological cancer or the initiation and/or progression of epithelial cancer such as lung, bladder, prostate or gynaecological cancer in a human comprising administering to the human of a combination dosage of a cyclooxygenase (COX) inhibitor, a vitamin D3 including analogues and metabolites thereof and/or calcium. In a further aspect the invention relates to a method for reducing the effective dosage of ASA in a chemopreventive treatment of epithelial cancer in a human by co-administration with a non toxic dosage of a vitamin D3 including analogues and metabolites thereof and/or Ca in the form of a combination dosage.
    Type: Application
    Filed: October 6, 2003
    Publication date: June 17, 2004
    Inventor: Hans Henrik Raskov
  • Patent number: 6747003
    Abstract: The invention provides vitamin K-dependent polypeptides with enhanced membrane binding affinity. These polypeptides can be used to modulate clot formation in mammals. Methods of modulating clot formation in mammals are also described.
    Type: Grant
    Filed: February 3, 2000
    Date of Patent: June 8, 2004
    Assignee: Regents of the University of Minnesota
    Inventor: Gary L. Nelsestuen
  • Publication number: 20040106584
    Abstract: This invention is directed to methods and compositions which impede the development and progression of diseases associated with subclinical inflammation. Subclinical inflammation is commonly associated with atherosclerotic cardiovascular disease, coronary disease or cerebrovascular disease. The methods and compositions of the invention are also particularly suited to providing therapy for subclinical inflammation in diabetic and prediabetic patients. Methods of the invention comprise administration of DHA alone and in combination with antiplatelet drugs.
    Type: Application
    Filed: September 29, 2003
    Publication date: June 3, 2004
    Inventors: Linda Arterburn, James Hoffman, Harry Oken, Mary Van Elswyk
  • Publication number: 20040102421
    Abstract: Anti-inflammatory compositions include medicaments comprising predetermined amounts of a phytyl substituted chromanol and a prostaglandin E2 inhibitor, wherein: said medicament is in unit dosage form suitable for pharmaceutical administration; said phytyl substituted chromanol is a gamma-tocopherol, delta-tocopherol, gamma-tocotrienol or delya-tocotrienol; said PGE2 inhibitor is a non-steroidal anti-inflammatory drug or an omega-3 fatty acid, such as docosahexaenoic acid and eicosapentaenoic acid.
    Type: Application
    Filed: November 21, 2002
    Publication date: May 27, 2004
    Applicant: Children's Hospital Research Center at Oakland
    Inventors: Bruce N. Ames, Qing Jiang
  • Publication number: 20040096521
    Abstract: Hairy hoof warts in animals are treated by topically administering an effective amount of a composition of aspirin or other compound or derivative of salicylic acid that preferably contains at least 50% by weight and more preferably between about 75% and 100% by weight aspirin or other compound or derivative of salicylic acid. A preferred composition includes aspirin, hydrated lime, sodium bentonite, and chalk or iron oxide.
    Type: Application
    Filed: November 14, 2002
    Publication date: May 20, 2004
    Inventor: Michael D. Clawson
  • Patent number: 6737042
    Abstract: The present invention relates to the delivery of drug esters through an inhalation route. Specifically, it relates to aerosols containing drug esters that are used in inhalation therapy. In a composition aspect of the present invention, the aerosol comprises particles comprising at least 5 percent by weight of drug ester. In a method aspect of the present invention, a drug ester is delivered to a mammal through an inhalation route. The method comprises: a) heating a composition, wherein the composition comprises at least 5 percent by weight of drug ester, to form a vapor; and, b) allowing the vapor to cool, thereby forming a condensation aerosol comprising particles, which is inhaled by the mammal.
    Type: Grant
    Filed: May 13, 2002
    Date of Patent: May 18, 2004
    Assignee: Alexza Molecular Delivery Corporation
    Inventors: Joshua D. Rabinowitz, Alejandro C. Zaffaroni
  • Publication number: 20040092592
    Abstract: Linking Magnesium ions to Nitric Oxide precursor L-Arginine, chemically 2-amino-5-guanidino valeric acid, with a platelet aggregation inhibitor compound such as, but not limited to acetylsalicylic acid or clopidogrel bisulfate, unexpectedly results in a pharmaceutically stabilized compositions with extended shelf life to be taken orally to provide gradual release vasodilatory and anti-platelet aggregation pharmacological activity with reduced potential for producing gastrointestinal lesions. L-Arginine releases ADNO (Arginine derived Nitric Oxide) in the coronary artery epithelium as EDRF (endothelium dependent relaxing factor) to dilate the arteries to promote blood flow to the myocardium, and the platelet aggregation inhibitor such acetylsalicylic acid or clopidogrel and others of this class of drugs inhibits or antagonizes the aggregation adhesion of platelets in the blood stream.
    Type: Application
    Filed: November 8, 2002
    Publication date: May 13, 2004
    Inventor: Leonard L. Kaplan
  • Publication number: 20040091557
    Abstract: Flexible elastomer articles and methods of making the same are disclosed in which a material, a botanical extract, is incorporated into an elastomer emulsion, solution and/or plastisol in order to enhance the physical and therapeutic properties of articles made from these materials. In another aspect, the invention relates to coating surfaces of flexible elastomer articles with a non-Aloe vera mucinous botanical or laboratory produced polysaccharide which is fortified by additives known to protect, restore and moisturize mammalian skin or mucosa and to enhance ease of application or donnability of the article. Flexible elastomer articles include gloves and other single layer or multi-layer flexible elastomer articles.
    Type: Application
    Filed: February 25, 2003
    Publication date: May 13, 2004
    Inventor: Curtis P. Hamann
  • Patent number: 6734210
    Abstract: Stable salts of azelaic acid with polycations such as chitosan are described. The salts according to the invention are water-soluble, therapeutically more efficacious and are valuable for use as active constituents in pharmaceutical as well as cosmeceutical compositions.
    Type: Grant
    Filed: February 23, 2001
    Date of Patent: May 11, 2004
    Inventor: Rolland F. Hebert
  • Publication number: 20040087558
    Abstract: Methods of treating, preventing, modifying and managing various types of pain are disclosed. Specific methods comprise the administration of a selective cytokine inhibitory drug, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active agent and/or surgery, psychological or physical therapy. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.
    Type: Application
    Filed: October 23, 2003
    Publication date: May 6, 2004
    Inventors: Jerome B. Zeldis, Herbert Faleck, Donald C. Manning
  • Publication number: 20040087492
    Abstract: The invention provides novel methods for treating disease based upon the medicinal use of lipids and phospholipids covalently bound to physiologically acceptable monomers or polymers. Phosphatidylethanolamine moieties conjugated to physiologically acceptable monomers and polymers (PE conjugates) manifest an unexpectedly wide range of pharmacological effects, including stabilizing cell membranes; limiting oxidative damage to cell and blood components; limiting cell proliferation, cell extravasation and (tumor) cell migratory behavior; suppressing immune responses; and attenuating physiological reactions to stress, as expressed in elevated chemokine levels.
    Type: Application
    Filed: July 28, 2003
    Publication date: May 6, 2004
    Inventors: Saul Yedgar, Miron Krimsky, Grietje Beck, Benito Antonio Yard, Fokko Johannes van der Woude
  • Patent number: 6730329
    Abstract: One aspect of the invention relates to anti-viral composition containing at least one zinc compound and at least one phenolic antioxidant (and optionally other ingredients such as at least one analgesic) at least one hydrocarbyl containing compound, and water. Another aspect of the invention relates to a method of treating lesionous symptoms of a viral infection involving applying an effective amount of the zinc containing anti-viral composition to the lesions.
    Type: Grant
    Filed: February 26, 2002
    Date of Patent: May 4, 2004
    Inventor: Jeffrey B. Smith
  • Publication number: 20040077609
    Abstract: Oral compositions for treating and/or preventing gingivitis are provided. The compositions include at least one NSAID, thymol, methyl salicylate, menthol and eucalyptol. The NSAID, thymol, methyl salicylate, menthol and eucalyptol are present in the composition in synergistically effective amounts. The compositions can be provided in the form of, e.g., mouthwashes or toothpastes, and are not only effective against gingivitis, but can also prevent or treat halitosis and other detrimental conditions of the oral cavity.
    Type: Application
    Filed: November 21, 2003
    Publication date: April 22, 2004
    Inventors: Michael Rubin, Pauline Pan, Frank Volpe
  • Publication number: 20040077604
    Abstract: A novel pharmaceutical composition is provided by which nonsteroidal anti-inflammatory drugs (NSAIDs) are added directly to phospholipid-containing oil such as lecithin oils or to a bio-compatible oil to which an phospholipid has been added to make a NSAID-containing formulation that possess low gastrointestinal (GI) toxicity and enhanced therapeutic activity to treat or prevent inflammation, pain, fever, platelet aggregation, tissue ulcerations and/or other tissue disorders. The composition of the invention are in the form of a non-aqueous solution, paste, suspension, dispersion, colloidal suspension or in the form of an aqueous emulsion or microemulstion for internal, oral, direct or topical administration.
    Type: Application
    Filed: November 6, 2003
    Publication date: April 22, 2004
    Inventor: Lenard Lichtenberger
  • Publication number: 20040067914
    Abstract: The present invention concerns esters of R-enantiomers of a non-steroidal anti-inflammatory drug, which is substantially free from the S-enantiomer. The compounds of the invention may be used in treating a disease or illness in a mammal. To this end, a composition comprising a compound mentioned above, or a pharmaceutically acceptable salt thereof where salt formation occurs, is administered to the mammal in an amount sufficient to elicit a chemopreventative effect or a chemoprotective effect or a therapeutic effect or a prophylactic effect.
    Type: Application
    Filed: October 3, 2003
    Publication date: April 8, 2004
    Inventors: William J. Wechter, Elaine Benaksas Schwartz
  • Patent number: 6716417
    Abstract: The present invention relates to the delivery of nonsteroidal antiinflammatory drugs (NSAIDs) through an inhalation route. Specifically, it relates to aerosols containing NSAIDs that are used in inhalation therapy. In a composition aspect of the present invention, the aerosol comprises particles comprising at least 5 percent by weight of an NSAID. In a method aspect of the present invention, an NSAID is delivered to a mammal through an inhalation route. The method comprises: a) heating a composition, wherein the composition comprises at least 5 percent by weight of an NSAID, to form a vapor; and, b) allowing the vapor to cool, thereby forming a condensation aerosol comprising particles, which is inhaled by the mammal.
    Type: Grant
    Filed: May 23, 2002
    Date of Patent: April 6, 2004
    Assignee: Alexza Molecular Delivery Corporation
    Inventors: Joshua D. Rabinowitz, Alejandro C. Zaffaroni
  • Publication number: 20040058019
    Abstract: A kit and method for treating migraine headaches comprising the preparing of an oral composition containing at least two bags of black pekoe tea brewed in approximately three ounces of boiling water for ten to thirty seconds. After brewing, the bags of tea are removed and two 325 mg aspirin tablets, one to two teaspoonfuls or tablets of apple cider vinegar, and one to three teaspoonfuls of honey are mixed into the brewed tea. The entire hot and concentrated composition is then cooled over ice so that a person suffering from a migraine headache may quickly drink it.
    Type: Application
    Filed: September 15, 2003
    Publication date: March 25, 2004
    Inventor: Suzanne Cruse
  • Patent number: 6709678
    Abstract: An oral composition which is adapted to be dispersed in an aqueous carrier substantially immediately prior to administration comprises a multiplicity of particles comprising an active substance, the particles being combined with one or more gelling or swelling agents capable of forming a viscous medium around the particles in an aqueous carrier as well as being provided with a masking surface layer when dispersed in the aqueous carrier. This serves to mask uneven surfaces on the particles and prevent them from adhering to oral mucosa when the composition is ingested and thus makes it easier to administer large dosages of an active substance. The masking surface layer is preferably provided by an increased viscosity of the viscous medium in the immediate vicinity of the particles relative to the viscosity of the surrounding aqueous carrier. A ready-to-use composition is prepared by mixing the composition with an aqueous carrier substantially immediately prior to administration of the composition.
    Type: Grant
    Filed: February 10, 1999
    Date of Patent: March 23, 2004
    Assignee: Losan Pharma GmbH
    Inventor: Peter Gruber
  • Publication number: 20040053205
    Abstract: Flush preservation solution for the preservation of cells in the absence of a blood supply comprising:
    Type: Application
    Filed: August 5, 2003
    Publication date: March 18, 2004
    Inventors: David Potts, Jeremy Peter Alan Lodge
  • Patent number: 6706290
    Abstract: Nanobacteria contribute to pathological calcification in the human and animal body, including diseases such as kidney stones, salivary gland stones, dental pulp stones and atherosclerosis. The present invention provides methods for sterilizing articles contaminated with nanobacteria. The present invention also provides methods of treating patients infected with nanobacteria. In particular, the present invention provides a method for preventing the recurrence of kidney stones in a patient that has suffered from kidney stones, comprising administration of an antibiotic, a bisphosphonate, or a calcium chelator, either alone or in combination, in an amount effective to inhibit or prevent the growth and development of nanobacteria.
    Type: Grant
    Filed: July 2, 1999
    Date of Patent: March 16, 2004
    Inventors: Olvai E. Kajander, Neva Ciftcioglu
  • Patent number: 6703380
    Abstract: The present invention relates to a method for the prevention of cancer or the initiation and/or progression of cancer in a human comprising administration to the human a combination dosage of a cyclooxygenase (COX) inhibitor, a vitamin D3 including analogues and metabolites thereof and calcium. In a further embodiment the invention relates to the use of the combination dosage for the preparation of a medicament and to such pharmaceutical preparations. In a further aspect the invention relates to a method for reducing the effective dosage of ASA in a chemoprofylactive treatment of colorectal cancer in a human by co-administration with a non toxic dosage of a vitamin D3 including analogues and metabolites thereof and Ca in the form of a combination dosage.
    Type: Grant
    Filed: April 5, 2001
    Date of Patent: March 9, 2004
    Assignees: Colotech A/S
    Inventor: Hans Henrik Raskov
  • Publication number: 20040043970
    Abstract: A method for reducing an antigen indicator of prostate cancer and for reducing the need for biopsies in men suspected of having prostate cancer and a method for treating patients with elevated PSA levels. In one method, the level of an antigen indicator of prostate cancer is measured and for an above normal level of the antigen indicator, an effective amount of an anti-inflammatory, or a combination of the anti-inflammatory and an antibiotic, is administered and the level of the antigen indicator is remeasured to determine if the level is normal or reduced, whereby a biopsy may not be indicated.
    Type: Application
    Filed: March 21, 2003
    Publication date: March 4, 2004
    Inventor: Harry Fisch
  • Publication number: 20040043082
    Abstract: Methods and preparations for treating disorders of the eye and/or causing dissolution of corneal proteoglycans and organized healing of corneal stroma, softening of the cornea for non-surgical refractive correction of eyesight, removing corneal haze and opacification, inhibiting fibroblasts and preventing corneal fibrosis and scar formation, treating pterigiums and treating corneal neovascularization as well as iris neovascularization. Preparations containing a) urea, b) urea derivatives (e.g., hydroxyurea, thiourea), c) antimetabolites, e) urea, urea derivatives, non-enzymatic proteins, nucleosides, nucleotides and their derivatives (e.g.
    Type: Application
    Filed: March 14, 2003
    Publication date: March 4, 2004
    Applicant: Vitreo-Retinal Technologies, Inc.
    Inventors: Vicken H. Karageozian, David Castillejos, John Park, Gabriel Arthuro Carpio Aragon, Jose Luis Gutierres Floress
  • Publication number: 20040037836
    Abstract: A method for preventing adverse effects associated with the use of a medical device in a patient by introducing into the patient a device of which at least a portion includes a prophylactic or therapeutic amount of a nitric oxide adduct. The nitric oxide adduct can be present in a matrix coating on a surface of the medical device; can be coated per se on a surface of the medical device; can be directly or indirectly bound to reactive sites on a surface of the medical device; or at least a portion of the medical device can be formed of a material, such as a polymer, which includes the nitric oxide adduct. Also disclosed is a method for preventing adverse effects associated with the use of a medical device in a patient by introducing the device during a medical procedure and before or during said procedure locally administering a nitric oxide adduct to the site of contact of said device with any internal tissue.
    Type: Application
    Filed: August 25, 2003
    Publication date: February 26, 2004
    Inventors: Jonathan Stamler, Joseph Loscalzo, John D. Folts
  • Publication number: 20040038948
    Abstract: Methods of promoting healing through enhanced regeneration of tissue (e.g. hard tissue or soft tissue) by contacting the tissue or the surrounding tissue with an anti-inflammatory agent. These methods are useful in a variety of dental and orthopedic applications.
    Type: Application
    Filed: February 18, 2003
    Publication date: February 26, 2004
    Inventor: Kathryn E. Uhrich
  • Publication number: 20040033223
    Abstract: The present invention provides pharmaceutical uses of betaines, and especially glycine betaine, such as for the treatment of thromboses not induced by hyperhomocystenemia or homocystinuria, of blood disorders, such as blood coagulation and thrombi formation.
    Type: Application
    Filed: August 4, 2003
    Publication date: February 19, 2004
    Inventor: Jallal Messadek
  • Publication number: 20040034098
    Abstract: Chronological aging of human skin can be delayed with the topical application of an MMP inhibitor, preferably a retinoid (an indirect MMP inhbitor); retinoids also normalize procollagen biosynthesis. Chronological aging, or natural aging, is evidenced in elderly (80+ years old) skin by increased MMP levels and decreased procollagen levels when compared with younger individuals. Prophylactic treatment of not yet chronologically-aged skin with a retinoid both inhibits degradation of dermal collagen and restores procollagen synthesis. Biopsied sections from elderly skin show that a single treatment of chronologically-aged skin with a retinoid can increase epidermal thickness, improve the dermal collagen density, and promote the formation of rete pegs and dermal papillae. Such benefits are helpful in preventing bruising, tearing, and ulceration of elderly skin. Accordingly, prophylactic treatment begun much earlier in life with an MMP inhibitor and/or a retinoid delays the onset of such symptoms.
    Type: Application
    Filed: June 10, 2003
    Publication date: February 19, 2004
    Inventors: James Varani, Gary J. Fisher, John J. Voorhees, Sewon Kang
  • Publication number: 20040033222
    Abstract: Disclosed are methods for a treating a disease or condition relating to blood coagulation and fibrinolysis using p38 MAP kinase inhibitors.
    Type: Application
    Filed: July 30, 2003
    Publication date: February 19, 2004
    Applicants: Boehringer Ingelheim Pharmaceuticals, Inc., Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Chester C. Wood, Tom van der Poll
  • Publication number: 20040033997
    Abstract: Compositions and methods for preventing sporadic neoplasia of the colon are provided. The compositions provided are based on administration of acetylsalicylic acid.
    Type: Application
    Filed: March 3, 2003
    Publication date: February 19, 2004
    Inventor: John A. Baron